Dr Campos discusses clinical implications from the gynecologic cancer cohorts of DESTINY-PanTumor02 and considerations for managing adverse effects in patients receiving T-DXd.
Susana Campos, MD, MPH
Advertisement
Articles by Susana Campos, MD, MPH
Managing Toxicities in Short- and Long-Term Treatment with ADCs
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.
Managing ILD and Pneumonitis Risk From ADCs
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.
The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Vijayakrishna Gadi, MD, PhD, discusses the role of antibody-drug conjugates in a curative setting.
Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
A panel of experts discuss the challenges of testing for HER2-low access solid tumor types.
ADCs Targeting HER2+ GU Cancers
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
A panel of experts discuss if there is a role for HER2-directed ADCs antibody-drug conjugates in GU genitourinary cancers
Impact of ADCs on Brain Metastases
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
A panel of experts discuss where HER2-directed ADCs antibody-drug conjugates fit into the overall treatment paradigm.
ADCs Targeting HER2+ Lung Cancer
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Dr Garon shares insights on the role of ADCs for the treatment of HER2+ lung cancer.
Dr Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.
ADCs Targeting GI Cancers
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.
Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of results from the DESTINY-PanTumor02 trial.
Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.
Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.
Susana Campos, MD, MPH, assistant professor of medicine, Harvard Medical School, and Dana-Farber Cancer Institute, discusses differences between PARP inhibitors in recurrent ovarian cancer.
Advertisement
Latest Updated Articles
ADCs Targeting HER2+ Lung CancerPublished: July 12th 2024 | Updated: July 12th 2024
- Assessing HER2 Status Across Tumor Types
June 25th 2024
- ADCs Targeting HER2+ Breast Cancer
June 25th 2024
- ADCs Targeting GI Cancers
Published: July 12th 2024 | Updated: July 12th 2024
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
Epcoritamab Plus Lenalidomide Improves PFS vs R-GemOx in R/R DLBCL
3
MANGROVE Trial Shows Improved Efficacy With Zanubrutinib Plus Rituximab vs Chemo in MCL
4
Experts Outline the Evolving Role of ctDNA-Based MRD Testing Across Solid Tumors
5